Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.